Tough UK line on funding rare-disease drugs raises concern
Adding a funding cap for new therapies could make it harder for drugmakers to recoup development costs
London
A TOUGHER stance in the UK on funding expensive medicines for rare diseases is raising questions about the government's pledges to support a life-sciences industry that's already rattled by Brexit.
A proposal to introduce a cap on coverage of treatments within the state-run health system would have a significant impact on access to ultra-rare disease drugs, said Heidi Wagner, senior vice-president of global government affairs at Alexion Pharmaceuticals Inc. Last week, the US biotech company was denied support in England for Kanuma, a drug that's estimated to cost £492,000 (S$869,000) a year, because a key authority deemed it too expensive even after unspecified discounts.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue